- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 06-01-2026: Press Release
06-01-2026 | 05:34 pm
06-01-2026 | 05:34 pm
Biocon Biologics expands its oncology portfolio with three new biosimilars, including Keytruda and Opdivo, tapping into an over $75 billion market opportunity. The company will also integrate as a wholly owned subsidiary into Biocon Ltd., strengthening its position in diabetes, oncology, and immunology.
No comments yet. Be the first to comment!